Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1375)
  2. Journal Article (1150)
  3. Review (130)
  4. Editorial (65)
  5. Research Letter (36)
  6. Book Section (25)
  7. Correspondence (24)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Hematology-Oncology Fellows (2747)
  2. Department of Medicine (2704)
  3. Solid Tumor Oncology Division (2003)
  4. Hematologic Malignancies, Division of (1330)
  5. GSK Faculty (1228)
  6. Department of Pathology and Laboratory Medicine (982)

More Groups

People
  1. Michael Berger (218)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (176)
  5. Sergio Giralt (171)
  6. Maria Carlo (168)

More People

Years
  1. 2025 (207)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (643)
  2. Elsevier Inc. (343)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (239)
  5. Nature Publishing Group (201)
  6. Oxford University Press (157)

More Publishers

Results (2820)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents
    Meeting Abstract

    Ged, Y.; Lee, C. H.; Sanchez, A.; Duzgol, C.; Chaim, J.; Carlo, M. I.; Foster, A.; Akin, O.; Feldman, D. R.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF)
    Meeting Abstract

    Ged, Y.; Gupta, R.; Duzgol, C.; Shapnik, N.; Redzematovic, A.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Detection of subthreshold microsatellite instability in breast cancer: An ongoing investigation
    Meeting Abstract

    Drago, J. Z.; Latham, A.; Modi, S.; Razavi, P.; Stadler, Z. K.; Robson, M. E.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC)
    Meeting Abstract

    dos Anjos, C. H.; Razavi, P.; Herbert, J.; Colon, J.; Gill, K.; Modi, S.; Bromberg, J.; Dang, C. T.; Liu, D.; Norton, L.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The prognostic significance of white adipose tissue inflammation in advanced-stage, high-grade, and serous endometrial cancers
    Meeting Abstract

    Broach, V.; Iyengar, N. M.; Zhou, X. K.; Wang, H.; Giri, D. D.; Williams, S.; Abu-Rustum, N.; Rubinstein, M. M.; Dannenberg, A. J.; Makker, V.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade
    Meeting Abstract

    Arbour, K. C.; Tuan, L. A.; Rizvi, H.; Yala, A.; Hellmann, M. D.; Barzilay, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%
    Meeting Abstract

    Jimenez Aguilar, E.; Ricciuti, B.; Gainor, J. F.; Nishino, M.; Adeni, A. E.; Subegdjo, S.; Khosrowjerdi, S.; Peterson, R.; Digumarthy, S.; Liu, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Benefit of early-phase targeted, basket, and immune-based trials for patients with chemorefractory gastrointestinal (GI) cancers
    Meeting Abstract

    Agarwal, R.; Cangemi, N. A.; Epstein, A. S.; Harding, J. J.; Segal, N. H.; Reidy, D. L.; Hyman, D. M.; Saltz, L. B.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save